Many cases of subacute thyroiditis (SAT) have been described related to SARS-CoV-2infection, but no prospective data about follow-up is known. This prospective,longitudinal, 3-year, multicentre study is aimed at exploring clinical peculiarities andoutcome of SAT in relation to SARS-CoV-2 infection, ascertained with antibody dosage.All patients receiving SAT diagnosis from November 2020 to May 2022 were enrolled.Multicentre study. Data about anamnesis, physical examination, blood tests (TSH, freeT4,freeT3, thyroglobulin, anti-thyroid antibodies, C-reactive protein, erythrocytesedimentation rate, complete blood count), and thyroid ultrasound were collected. Atbaseline, the presence of IgG against the SARS-CoV-2 spike protein or nucleocapside wasinvestigated. Patients were evaluated after 1, 3, 6, 12 months.
A multicentre, longitudinal, prospective study was conducted, enrolling all patients
diagnosed with SAT at the participating centres between November 2020 and May 2022. The
following Italian centres participated: Endocrinology Unit of Azienda
Ospedaliero-Universitaria of Modena (Coordinating center); Endocrinology Unit of IRCCS
Ca' Granda Ospedale Maggiore Policlinico of Milano; Endocrinology and Diabetes Prevention
and Care Unit of the IRCCS Azienda Ospedaliero-Universitaria Policlinico of Bologna.
These Units were involved through a call launched by the coordinating center to the young
Italian members of the Club EnGioI (Endocrinologia Giovane in Italia) of the Italian
Society of Endocrinology (SIE).
Five visits were planned: at diagnosis (V0) and after 1, 3, 6 and 12 months (V1, V2, V3
and V4, respectively). At each visit, subjects were evaluated with anamnesis, physical
examination, thyroid ultrasound and blood tests. Patients were treated according to the
clinical presentation and to the current guidelines. Nonsteroidal anti-inflammatory drugs
(NSAIDs) were preferred in patients with mild symptoms and mild laboratory findings;
steroid therapy was preferred in those with severe symptoms and/or those who did not
respond to NSAIDs within 1 to 2 weeks. Beta-blockers were prescribed as symptomatic
treatment in case of tachycardia. During the follow-up phase, the therapeutic approach
and any change of it were recorded.
Finally, the treatment responsiveness and outcomes of transient hypothyroidism, permanent
hypothyroidism, or recurrence during the follow-up period were all documented.
Diagnostic Test: Blood sample, CRF, thyroid ultrasound
Five visits were planned: at diagnosis (V0) and after 1, 3, 6 and 12 months (V1, V2, V3
and V4, respectively). At each visit, subjects were evaluated with anamnesis, physical
examination, thyroid US and blood tests.
Inclusion Criteria:
- clinical diagnosis of subacute thyroiditis
- age ≥ 18 years
- willingness to sign an informed consent
Exclusion Criteria:
- ongoing pregnancy
- alcohol abuse.
University of Modena and Reggio Emilia
Modena 3173331, Italy
Not Provided